|
US5187157A
(en)
|
1987-06-05 |
1993-02-16 |
Du Pont Merck Pharmaceutical Company |
Peptide boronic acid inhibitors of trypsin-like proteases
|
|
GB9019558D0
(en)
|
1990-09-07 |
1990-10-24 |
Szelke Michael |
Enzyme inhibitors
|
|
SE9301911D0
(sv)
|
1993-06-03 |
1993-06-03 |
Ab Astra |
New peptide derivatives
|
|
US5589467A
(en)
|
1993-09-17 |
1996-12-31 |
Novo Nordisk A/S |
2,5',N6-trisubstituted adenosine derivatives
|
|
US5786328A
(en)
|
1995-06-05 |
1998-07-28 |
Genentech, Inc. |
Use of kunitz type plasma kallikrein inhibitors
|
|
US7101878B1
(en)
|
1998-08-20 |
2006-09-05 |
Agouron Pharmaceuticals, Inc. |
Non-peptide GNRH agents, methods and intermediates for their preparation
|
|
EP1169038B9
(en)
|
1999-04-15 |
2013-07-10 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
ATE355064T1
(de)
|
2001-10-26 |
2006-03-15 |
Angeletti P Ist Richerche Bio |
Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
|
|
WO2003037274A2
(en)
|
2001-11-01 |
2003-05-08 |
Icagen, Inc. |
Pyrazole-amides and-sulfonamides
|
|
GB0205527D0
(en)
|
2002-03-08 |
2002-04-24 |
Ferring Bv |
Inhibitors
|
|
AU2003230829B8
(en)
|
2002-04-26 |
2008-12-11 |
Eli Lilly And Company |
Triazole derivatives as tachykinin receptor antagonists
|
|
EP1426364A1
(en)
|
2002-12-04 |
2004-06-09 |
Aventis Pharma Deutschland GmbH |
Imidazole-derivatives as factor Xa inhibitors
|
|
DE10301300B4
(de)
|
2003-01-15 |
2009-07-16 |
Curacyte Chemistry Gmbh |
Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
|
|
US20040192728A1
(en)
|
2003-02-03 |
2004-09-30 |
Ellen Codd |
Quinoline-derived amide modulators of vanilloid VR1 receptor
|
|
NZ592039A
(en)
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
|
TW200526588A
(en)
|
2003-11-17 |
2005-08-16 |
Smithkline Beecham Corp |
Chemical compounds
|
|
GB0403155D0
(en)
|
2004-02-12 |
2004-03-17 |
Vernalis Res Ltd |
Chemical compounds
|
|
EP1568698A1
(en)
|
2004-02-27 |
2005-08-31 |
Aventis Pharma Deutschland GmbH |
Pyrrole-derivatives as factor Xa inhibitors
|
|
US7429604B2
(en)
|
2004-06-15 |
2008-09-30 |
Bristol Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
|
ATE518858T1
(de)
|
2004-09-03 |
2011-08-15 |
Yuhan Corp |
Pyrroloä3,2-cüpyridinderivate und herstellungsverfahren dafür
|
|
EP1858542A4
(en)
|
2005-02-24 |
2009-08-19 |
Joslin Diabetes Center Inc |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
|
|
GB0508472D0
(en)
|
2005-04-26 |
2005-06-01 |
Glaxo Group Ltd |
Compounds
|
|
KR101142363B1
(ko)
|
2005-06-27 |
2012-05-21 |
주식회사유한양행 |
피롤로피리딘 유도체를 포함하는 항암제 조성물
|
|
EA200800321A1
(ru)
|
2005-07-14 |
2008-06-30 |
Такеда Сан Диего, Инк. |
Ингибиторы гистондеацетилазы
|
|
US20070254894A1
(en)
|
2006-01-10 |
2007-11-01 |
Kane John L Jr |
Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
|
|
GB0606876D0
(en)
|
2006-04-05 |
2006-05-17 |
Glaxo Group Ltd |
Compounds
|
|
US20070258976A1
(en)
|
2006-05-04 |
2007-11-08 |
Ward Keith W |
Combination Therapy for Diseases Involving Angiogenesis
|
|
MX2009000117A
(es)
|
2006-07-06 |
2009-01-23 |
Glaxo Group Ltd |
N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.
|
|
WO2008016883A2
(en)
|
2006-07-31 |
2008-02-07 |
Activesite Pharmaceuticals, Inc. |
Inhibitors of plasma kallikrein
|
|
DE102006050672A1
(de)
|
2006-10-24 |
2008-04-30 |
Curacyte Discovery Gmbh |
Hemmstoffe des Plasmins und des Plasmakallikreins
|
|
AR064693A1
(es)
|
2006-12-29 |
2009-04-22 |
Abbott Gmbh & Co Kg |
Compuestos carboxamidas y su utilizacion en la elaboracion de un medicamento para el tratamiento de enfermedades asociadas a alta actividad de calpaina.
|
|
US20100119512A1
(en)
|
2007-01-25 |
2010-05-13 |
Joslin Diabetes Center |
Methods of diagnosing, treating, and preventing increased vascular permeability
|
|
JP2010520293A
(ja)
|
2007-03-07 |
2010-06-10 |
アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド |
複素環式部分を含有するメタロプロテアーゼ阻害剤
|
|
NZ579892A
(en)
|
2007-03-30 |
2012-03-30 |
Sanofi Aventis |
Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
|
|
MX2009010759A
(es)
|
2007-04-03 |
2009-10-28 |
Glaxo Group Ltd |
Derivados de carboxamida imidazolidina como modulares de p2x7.
|
|
CN101778827B
(zh)
|
2007-07-26 |
2012-10-10 |
先正达参股股份有限公司 |
杀微生物剂
|
|
EP2185506A1
(en)
|
2007-08-22 |
2010-05-19 |
Allergan, Inc. |
Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
|
|
WO2009086303A2
(en)
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Method for altering the lifespan of eukaryotic organisms
|
|
WO2009083553A1
(en)
|
2007-12-31 |
2009-07-09 |
Rheoscience A/S |
Azine compounds as glucokinase activators
|
|
EP2259679A4
(en)
|
2008-01-31 |
2011-09-14 |
Joslin Diabetes Ct |
METHODS OF TREATING KALLIKREIN RELATED DISORDERS
|
|
WO2009106980A2
(en)
|
2008-02-29 |
2009-09-03 |
Pfizer Inc. |
Indazole derivatives
|
|
US8324199B2
(en)
|
2008-03-13 |
2012-12-04 |
Bristol-Myers Squibb Company |
Pyridazine derivatives as factor xia inhibitors
|
|
TWI435875B
(zh)
|
2008-07-08 |
2014-05-01 |
Daiichi Sankyo Co Ltd |
含氮芳香族雜環化合物
|
|
US8324385B2
(en)
|
2008-10-30 |
2012-12-04 |
Madrigal Pharmaceuticals, Inc. |
Diacylglycerol acyltransferase inhibitors
|
|
GB0910003D0
(en)
|
2009-06-11 |
2009-07-22 |
Univ Leuven Kath |
Novel compounds for the treatment of neurodegenerative diseases
|
|
AU2010330743A1
(en)
|
2009-12-18 |
2012-07-05 |
Activesite Pharmaceuticals, Inc. |
Prodrugs of inhibitors of plasma kallikrein
|
|
JP2011157349A
(ja)
|
2010-01-07 |
2011-08-18 |
Daiichi Sankyo Co Ltd |
含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
|
|
MX345259B
(es)
|
2010-01-28 |
2017-01-23 |
The Medicines Company (Leipzig) Gmbh |
Inhibidores de serina proteasas similares a tripsina, y su preparación y uso.
|
|
JP2013121919A
(ja)
|
2010-03-25 |
2013-06-20 |
Astellas Pharma Inc |
血漿カリクレイン阻害剤
|
|
WO2012004678A2
(en)
|
2010-07-07 |
2012-01-12 |
The Medicines Company (Leipzig) Gmbh |
Serine protease inhibitors
|
|
EP2595986A2
(en)
|
2010-07-14 |
2013-05-29 |
Addex Pharma SA |
Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
|
|
US9290485B2
(en)
*
|
2010-08-04 |
2016-03-22 |
Novartis Ag |
N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
|
|
EP2458315B1
(de)
|
2010-11-25 |
2017-01-04 |
Balcke-Dürr GmbH |
Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung
|
|
WO2012142308A1
(en)
|
2011-04-13 |
2012-10-18 |
Activesite Pharmaceuticals, Inc. |
Prodrugs of inhibitors of plasma kallikrein
|
|
WO2012174362A1
(en)
|
2011-06-17 |
2012-12-20 |
Research Triangle Institute |
Pyrazole derivatives as cannabinoid receptor 1 antagonists
|
|
GB2494851A
(en)
|
2011-07-07 |
2013-03-27 |
Kalvista Pharmaceuticals Ltd |
Plasma kallikrein inhibitors
|
|
EP2760828B1
(en)
|
2011-09-27 |
2015-10-21 |
Bristol-Myers Squibb Company |
Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
|
|
EP2760829B1
(en)
|
2011-09-27 |
2016-05-18 |
Bristol-Myers Squibb Company |
Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
|
|
US20140378474A1
(en)
|
2012-01-27 |
2014-12-25 |
Novartis Ag |
5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
|
|
EP2807156A1
(en)
|
2012-01-27 |
2014-12-03 |
Novartis AG |
Aminopyridine derivatives as plasma kallikrein inhibitors
|
|
JP5989805B2
(ja)
|
2012-02-10 |
2016-09-07 |
コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
メチル基変更酵素の調節物質、組成物及びその使用
|
|
WO2013130603A1
(en)
|
2012-02-27 |
2013-09-06 |
Board Of Regents, The University Of Texas System |
Ganglioside gd2 as a marker and target on cancer stem cells
|
|
GB201212081D0
(en)
|
2012-07-06 |
2012-08-22 |
Kalvista Pharmaceuticals Ltd |
New polymorph
|
|
CA2894642A1
(en)
|
2013-01-08 |
2014-07-17 |
Savira Pharmaceuticals Gmbh |
Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
|
|
GB201300304D0
(en)
*
|
2013-01-08 |
2013-02-20 |
Kalvista Pharmaceuticals Ltd |
Benzylamine derivatives
|
|
GB2510407A
(en)
|
2013-02-04 |
2014-08-06 |
Kalvista Pharmaceuticals Ltd |
Aqueous suspensions of kallikrein inhibitors for parenteral administration
|
|
EP4234583A3
(en)
|
2013-01-20 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Evaluation and treatment of bradykinin-mediated disorders
|
|
LT2968297T
(lt)
|
2013-03-15 |
2019-01-10 |
Verseon Corporation |
Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
|
|
EP2999697B1
(en)
|
2013-05-23 |
2017-04-19 |
Kalvista Pharmaceuticals Limited |
Heterocyclic derivates
|
|
GB2517908A
(en)
|
2013-08-14 |
2015-03-11 |
Kalvista Pharmaceuticals Ltd |
Bicyclic inhibitors
|
|
HUE14755117T2
(hu)
|
2013-08-14 |
2018-12-28 |
Kalvista Pharmaceuticals Ltd |
Plazma-kallikrein inhibitorok
|
|
US9611252B2
(en)
|
2013-12-30 |
2017-04-04 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
CA2935683A1
(en)
|
2013-12-30 |
2015-07-09 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
KR102736869B1
(ko)
|
2014-03-07 |
2024-12-02 |
바이오크리스트파마슈티컬즈,인코포레이티드 |
인간 혈장 칼리크레인 저해제
|
|
WO2015171527A1
(en)
|
2014-05-05 |
2015-11-12 |
Global Blood Therapeutics, Inc. |
Pyrazolopyridine pyrazolopyrimidine and related compounds
|
|
WO2015171526A2
(en)
|
2014-05-05 |
2015-11-12 |
Global Blood Therapeutics, Inc. |
Tricyclic pyrazolopyridine compounds
|
|
AU2015289643B2
(en)
|
2014-07-16 |
2020-10-22 |
Attune Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
JP6824876B2
(ja)
|
2014-08-22 |
2021-02-03 |
バイオクライスト ファーマシューティカルズ， インコーポレイテッド |
アミジン誘導体組成物及びそれらの使用
|
|
CN106687445A
(zh)
|
2014-09-17 |
2017-05-17 |
维颂公司 |
作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
|
|
GB201421083D0
(en)
*
|
2014-11-27 |
2015-01-14 |
Kalvista Pharmaceuticals Ltd |
Enzyme inhibitors
|
|
GB201421088D0
(en)
|
2014-11-27 |
2015-01-14 |
Kalvista Pharmaceuticals Ltd |
New enzyme inhibitors
|
|
GB201421085D0
(en)
|
2014-11-27 |
2015-01-14 |
Kalvista Pharmaceuticals Ltd |
New enzyme inhibitors
|
|
RU2017131562A
(ru)
|
2015-02-27 |
2019-03-27 |
Версеон Корпорейшн |
Замещенные пиразольные соединения как ингибиторы сериновых протеаз
|
|
US10981893B2
(en)
|
2015-07-01 |
2021-04-20 |
Attune Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
CA2991174A1
(en)
|
2015-07-01 |
2017-01-05 |
Lifesci Pharmaceuticals, Inc. |
Therapeutic inhibitory compounds
|
|
WO2017072020A1
(en)
|
2015-10-27 |
2017-05-04 |
Boehringer Ingelheim International Gmbh |
Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
|
|
EP3368524B1
(en)
|
2015-10-27 |
2021-08-18 |
Boehringer Ingelheim International GmbH |
Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
|
|
GB201609519D0
(en)
|
2016-05-31 |
2016-07-13 |
Kalvista Pharmaceuticals Ltd |
Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
|
|
DK3464271T3
(da)
|
2016-05-31 |
2020-06-15 |
Kalvista Pharmaceuticals Ltd |
Pyrazolderivater som plasma-kallikreininhibitorer
|
|
GB201609607D0
(en)
|
2016-06-01 |
2016-07-13 |
Kalvista Pharmaceuticals Ltd |
Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
|
|
GB201609603D0
(en)
|
2016-06-01 |
2016-07-13 |
Kalvista Pharmaceuticals Ltd |
Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
|
|
GB201609601D0
(en)
|
2016-06-01 |
2016-07-13 |
Nucana Biomed Ltd |
Phosphoramidate compounds
|
|
GB201609602D0
(en)
|
2016-06-01 |
2016-07-13 |
Nucuna Biomed Ltd |
Chemical compounds
|
|
CN110022875A
(zh)
|
2016-07-11 |
2019-07-16 |
莱福斯希医药公司 |
治疗性抑制化合物
|
|
WO2019106359A1
(en)
|
2017-11-29 |
2019-06-06 |
Kalvista Pharmaceuticals Limited |
Enzyme inhibitors
|
|
GB201719881D0
(en)
|
2017-11-29 |
2018-01-10 |
Kalvista Pharmaceuticals Ltd |
Solid forms of plasma kallikrein inhibitor and salts thereof
|
|
GB201719882D0
(en)
|
2017-11-29 |
2018-01-10 |
Kalvista Pharmaceuticals Ltd |
Solid forms of a plasma kallikrein inhibitor and salts thereof
|